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Abstract
Background: Parkinson’s Disease is a progressive neurodegenerative disease, characterized by symptoms of motor
impairment, resulting from the loss of dopaminergic neurons in the midbrain, however non-neuronal symptoms are
also common. Although great advances have been made in the pathogenic understanding of Parkinson’s Disease
in the nervous system, little is known about the molecular alterations occurring in other non-neuronal organ systems.
In addition, a higher rate of melanoma and non-melanoma skin cancer has been observed in the Parkinson’s Disease
population, indicating crosstalk between these diseases.
Methods: To understand the molecular pathogenesis and gene expression alterations of Parkinson’s Disease in
peripheral tissues, and in order to explore the possible link between skin cancer and neurodegeneration, whole
transcriptomic profiling of patients’ skin was performed. Skin biopsies from 12 patients and matched controls
were collected, and processed with high-throughput RNA-sequencing analysis.
Results: This analysis resulted in a large collection of over 1000 differentially expressed genes, among which clear
biological and functional networks could be distinguished. The central functional processes altered in patients skin can
be grouped into six broad categories: impaired cellular metabolism and mitochondrial dysfunction, defective protein
metabolism, disturbed skin homeostasis, dysfunctional nuclear processes, altered signalling and tumour pathways, as
well as disordered immune regulation.
Conclusions: These results demonstrate that the molecular alterations leading to neurodegeneration in the CNS are
systemic and manifest also in peripheral tissues, thereby indicating the presence of “skin-brain” crosstalk in Parkinson’s
Disease. In addition, the extensive homeostatic imbalance and basal stress can lead to increased susceptibility to
external and internal mutagenic hazards in these patients, and thus provide a possible molecular link for the
crosstalk between skin cancer and Parkinson’s Disease.
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Background
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder characterized by symptoms of resting tremor,
rigidity, bradykinesia and postural instability. The
motor symptoms of PD are considered to result from
the loss of substantia nigra dopaminergic neurons,
however patients experience also numerous non-motor
symptoms, due to involvement of central and peripheral
organ systems [1]. The non-motor symptoms are fre-
quently under-recognized and under-treated, although
they greatly impact the life quality of PD patients and can
often be the first indication of PD pathology, proceeding
the onset of motor-symptoms by several years [2], thus it
has been suggested that PD should no longer be viewed
solely as a dopamine-mediated basal ganglia disease,
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but rather as a multisystem progressive disorder [3].
The pathogenesis of PD is complex and likely caused
by a deregulated network of interconnected pathways,
including mitochondrial dysfunction, bioenergy failure,
oxidative stress, defective protein processing, endoplas-
matic reticulum stress, as well as decreased levels of
neurotrophic growth factors and activation of immune
mechanisms [4, 5]. The traditional hallmark of PD is
the presence of α-synuclein aggregates (Lewy Bodies-LB)
in the CNS, however these aggregates have been shown to
manifest also in the peripheral nervous system. Numerous
studies have investigated the pathogenic processes occur-
ring in the nervous system, however the reflection of
disease pathology in the peripheral tissues, has been
poorly characterized. In addition, due to lack of diag-
nostic and prognostic biomarkers a definitive diagnosis
for PD can only be performed post-mortem, thus informa-
tion on PD pathogenesis, with possible outlook on
novel biomarkers or disease-modifying therapy, is of
great value.
PD patients present with several skin symptoms
including cutaneous neuropathy, seborrhoea, hyperhi-
drosis and impaired wound healing [6]. A further link to
skin involvement in PD has been provided by studies
demonstrating the presence of cutaneous denervation
and α-synuclein deposits in dermal somatosensory
and autonomic nerve fibres [7, 8]. The extent of skin
denervation and aggregate deposition, is considered
to correlate with LB pathology in the brain [7], rendering
easily obtainable skin biopsy samples useful for pathogenic
studies and for novel biomarker discovery. The hypo-
thetical existence of a link between cancer and neuro-
degeneration has been under debate for some years,
and is based mostly on epidemiological observations of
patients with neurodegenerative diseases, who in general
exhibit a reduced incidence of many common types of
cancers. This holds true for PD, where a negative inter-
action between most cancers and PD has been estab-
lished, however an increased risk for both melanoma
and non-melanoma skin cancer has been found to be
strongly associated to PD, as epidemiological studies
have demonstrated an up to 4 fold increased risk for
melanoma and non-melanoma skin cancers [9–11] in
these patients. This crosstalk seems to be bidirectional
as the diagnosis of cutaneous melanoma is also associated
with a 2 fold increased risk for subsequent development
of PD [12]. The causal relationship and underlying
molecular mechanisms between these two diseases have
remained unclear, however suggested common mecha-
nisms include dysfunction in melanin/neuromelanin path-
ways, tyrosine metabolism, α-synuclein pathology,
activation and deregulation of the cell cycle, but also the
genetic aspect as familial PD gene variations have been
identified in skin cancers [13–15].
There are indications that PD also manifests in peripheral
tissues, as demonstrated by skin symptoms, dermal de-
nervation and α-synuclein deposition, however the precise
molecular basis for PD pathology in skin is unknown. In
addition, the increased risk of skin cancer in PD patients
suggests that common deregulated pathways exist be-
tween these diseases, however the exact pathogenic
mechanisms for this crosstalk have remained unclear.
Numerous gene expression profiling studies have been
performed on different PD models, including animal
models and human post-mortem brain tissues, however
none of the studies have evaluated the gene expression
patterns in peripheral solid tissues of PD patients. In
our study we utilized large-scale transcriptomic analysis
from whole skin puncture biopsy material, which repre-
sents the gene expression signal from all cells of epidermal
and dermal layers. The aim of the current study was to
test the hypothesis that the generalized biomolecular
defect observed in the nervous system is systemic and
present also in non-neuronal peripheral tissues, and to
analyse whether these alterations could provide evidence
for the crosstalk between PD and skin cancer.
Methods
Study subjects and ethics
The study was conducted in accordance with the Dec-
laration of Helsinki and approval was granted by the
Tartu University Ethics Committee. Informed consent
was obtained from all patients and controls. 12 PD
patients who fulfilled the Queen Square Brain Bank
diagnostic criteria [16, 17] and 12 healthy controls were
selected for RNA sequencing. The demographic data,
history of disease and clinical data were documented
and a summary of participant characteristics is pre-
sented in Additional file 1: Table S1. Disease severity,
disability and cognitive state were assessed using vali-
dated instruments including the Movement Disorders
Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS) [18, 19], the Hoehn and Yahr Scale (HY) [20],
the Schwab and England Activities of Daily Living Scale
(SE-ADL) [21] and the Mini Mental State Examination
(MMSE) [22]. The presence of familial PD and cancers
were excluded for all patients at the time of inclusion.
In addition, all concomitant medications were docu-
mented and none of the patients were taking any medi-
cations other than the commonly used dopaminergic
medications. The RNAseq control group consisted of 6
males (mean age 70 years) and 6 females (mean age
73 years). To assess the medical status and to exclude any
history of neurodegenerative disease, a medical interview
was performed for all control patients. Validation ana-
lysis of RNA sequencing data was performed on 37
patients of which 18 were males (mean age 69.3 years)
and 19 females (mean age 70 years) and 32 controls of
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which 15 were males (mean age 68.5 years) and 17
females (mean age 68.2 years). The clinical characteris-
tics of the PD patient cohort used for qRT-PCR analysis
is presented in Additional file 1: Table S9.
Experimental design, tissue sampling and RNA extraction
One 4 mm punch-biopsy specimen was taken from non-
sun-exposed skin of each subject from both study
groups. All biopsy specimens were instantly frozen in
liquid nitrogen and stored at -80C° until RNA extrac-
tion. Biopsies were homogenized with Precellys24
homogenizer with the Cryolys system (Bertin Tech-
nologies). RNeasy Fibrous Tissue Mini Kit (Qiagen) was
used for total RNA extraction, according to the manu-
facturer’s protocol. During the purification on-column
DNase I treatment was performed (Qiagen). The RNA
quality was assessed using Agilent 2100 Bioanalyzer, the
RNA 6000 Nano kit (Agilent Technologies) and the
Qubit fluorometer (Life Technologies). The lowest RIN
of study samples was 6.7.
Whole transcriptome sequencing (RNA-seq)
Fifty nanogram of each total RNA sample was amplified
with Ovation RNA-Seq System V2 Kit (NuGen) and the
output double stranded DNA was used to prepare
SOLiD 5500 System DNA fragment libraries according
to manufacturers’ protocols (LifeTechnologies). For library
preparation the barcoding adapters were used and 12
libraries were pooled prior sequencing. For sequencing
the SOLiD 5500 XL platform and paired-end sequencing
chemistry was applied (75 bp in forward and 35 bp in
reverse directions). In case of 12 samples per three
flowchip lanes approximately 40 million mappable reads
were expected per one sample, which is enough for suc-
cessful whole transcriptome expression pattern analysis.
Real-Time quantitative PCR
For validation of RNA sequencing data total RNA from
37 patients and 32 controls (including the 12 + 12 samples
from RNAseq) was converted to cDNA using random
primers and High Capacity cDNA Reverse Transcription
Kit with RNase Inhibitor (Applied Biosystems). Duplex
quantitative real-time PCR (qRT-PCR) analysis was per-
formed using TaqMan Gene Expression Assays with VIC
(housekeeping gene ActinB) and FAM (gene of interest)
probes and TaqMan® Gene Expression Master Mix
(Applied Biosystems). The TaqMan® Gene Assay IDs were
the following: Hs01060665_g1 (ActinB), Hs00761940_s1
(SAA-1), Hs00754237_s1 (SAA-2), Hs00361191_g1
(HBA-2), Hs00758338_g1 (CALML-6), Hs00819920_mH
(DGCR-6 L), Hs01012810_g1 (CST E/M), Hs00962118_g1
(OR2HR), Hs00603977_m1 (ROMO-1), Hs00936068_m1
(ADAMDEC), Hs01891339_s1 (HCRT), Hs01652462_m1
(KLRC-3), Hs00155790_m1 (APOC-1). RT-PCR was
performed using ABI PRISM 7900HT Fast Real-Time PCR
System equipment (Applied Biosystems) and the ABI
PRISM 7900 SDS 2.2.2 Software. Each reaction was made
in four replicates to minimize technical errors.
Data analysis and statistics
For analysis of RNAseq data Lifescope software was
used. For statistical analysis DeSeq package for R [23]
was used to test for differential expression by use the
negative binomial distribution and a shrinkage estimator
for the distribution’s variance. Package performs samples
comparison and also adjusts P-value to overcome multiple
testing problem. DeSeq package uses Benjamini-Hochberg
procedure, which controls for false discovery rate (FDR).
Functional pathway analysis was performed using the
QIAGEN’s Ingenuity® Pathway Analysis (QIAGEN
Redwood Citytool), followed by manual classification
of the selected genes into broad functional categories.
Based on the 10 major functional networks provided
by Ingenuity Pathway Analysis we narrowed our
framework of manual classification into 6 broad func-
tional categories in association to Parkinson’s Disease,
for which we used Pubmed searches initially for the
role of the specific gene and then searching for the as-
sociation with keywords such as “Parkinson’s Disease”
“neurodegeneration” “neuro” “Alzheimer’s Disease”,
“brain”. Each gene was categorized only once, according
to the more prominent functional role in association to
Parkinson’s Disease.
For analysis of real-time PCR the samples were nor-
malized to the corresponding housekeeping gene
Actin-B and the comparative ΔΔCT method was used
to calculate the fold change for all the samples.
Results
Differential expression of genes in PD skin
The RNA sequencing analysis of PD and control skin
resulted in 1074 genes to be differentially regulated be-
tween control and PD samples, with a FDR ≤ 0.05. A heat-
map of the 50 most significantly changed genes in the PD
versus control sample is shown in Fig. 1. Most of the
altered genes in our study showed decreased expression in
the PD samples: 82% (877 genes) down- and 18% (197
genes) up-regulated. The Ingenuity Pathway Analysis
resulted in 10 major functional networks to be influenced
by PD including (Table 1.): 1) gene expression, protein
synthesis, dermatological disease and conditions (refer-
ence score of 46, with 28 focus molecules differentially
expressed between PD and normal skin); 2) dermato-
logical diseases and conditions, immunological disease
and inflammatory disease (35/23); 3) cellular assembly
and organization, behaviour, cell signalling (34/23); 4)
cancer, immunological disease, cellular development
(33/22); 5) connective tissue disorder, dermatological
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diseases and conditions, developmental disorder (30/21);
6) lipid metabolism, molecular transport, small molecule
biochemistry (28/21); 7) molecular transport, neurological
disease, psychological disorders (28/20); 8) cellular
movement, haematological system development and
function, immune cell trafficking (21/18); 9) cellular
growth and proliferation, haematological system develop-
ment and function, tissue development (21/16); 10) lipid
metabolism, small molecule biochemistry, vitamin and
mineral metabolism (19/16). Due to the limitations of the
computer-based functional analysis, which managed to
classify only a small proportion of genes under specific
categories, we performed further manual classification
of the differentially expressed genes, which resulted in
6 broad functional categories including: cellular me-
tabolism/mitochondrial dysfunction (23% of genes);
protein metabolism/transport (16%); skin homeostasis
(11%); regulation of nuclear processes (12%); cellular
signalling and tumorigenesis (7%); immunological pro-
cesses (7%) and others. A full list of gene expression data
for all genes in our study can be found in Additional file 2.
Impaired cellular metabolism and mitochondrial
dysfunction
The largest group of genes altered in PD skin involves
the regulation of cellular metabolism and mitochondrial
dysfunction, with 252 genes classified in this category,
most of them being downregulated in PD (see Additional
file 1: Table S2). Apparent from these results is the severe
defect in mitochondrial respiration, as 36 genes of the
mitochondrial respiratory complex (out of 96 genes) were
supressed, including complex I (18 out of 44), complex III
(5 out of 10), complex IV (7 out of 19) and complex V
(6 out of 19). Of special note in regard to the metabolic
alterations in PD skin, is the increased expression of
peroxisome proliferator-activated receptor gamma
coactivator-1α (PPARGC1A or PGC-1α), which has been
considered to be the central inducer of mitochondrial
biogenesis in mammalian cells. In addition, many genes
in the cellular metabolism category are associated with
oxidative/peroxidative metabolism and the antioxidant
response, with 25 of the down-regulated genes playing
a role in this process, highlighted by deregulation of
central oxidative stress genes such as glutaredoxin 2
and 5, cystatin E/M and B, glutathione peroxidase and
transferases, different peroxiredoxins and reactive oxygen
species modulators. In addition several metallothioneins
were downregulated in PD skin. Only two of oxidative
stress response mediators were up-regulated: glutathione
S-transferase-mu1 and peroxidasin homolog. Another
large group of genes differentially expressed in PD skin is
associated with fatty acid metabolism, with 30 of the
down- and only 3 of the up-regulated genes falling into
this metabolic pathway. Processes involved include all
aspects of fatty acid metabolism including synthesis
and degradation by beta-oxidation, as well as binding
and transport. Also 3 members of the phospholipase
A2 group were down-regulated in PD samples, indicating
dysfunctional phospholipid digestion and metabolism in
PD. Other affected cellular metabolic processes include
the oxidation of aldehydes, central mitochondrial trans-
port genes, differential expression of mitochondrial
ribosomal proteins (12 members), purine/pyrimidine
metabolism, steroidogenesis, glucose/carbohydrate, amino
acid and iron/metal metabolism and detoxification.
Impaired protein metabolism
Impaired protein aggregation and degradation in the
nervous system has been linked to PD by many studies.
We hereby demonstrate widespread defects in protein
metabolism occurring in PD patient’s skin, with 170
genes being affected (see Additional file 1: Table S3.).
Similarly to the above mentioned metabolic processes,
most of the genes in this group also showed decreased
expression in PD (155 vs 15). Among these were genes
regulating protein translation, including 8 eukaryotic
elongation and initiation factors, a large group of riboso-
mal proteins (26 genes) and several genes mediating post-
translational modification. Of special note, in relation to
PD pathogenesis, is the deregulation of a group of genes
which play a role in protein folding and the unfolded
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Fig. 1 Hierarchical clustering (heat-map) demonstrating the expression
profiles of the top 50 differentially regulated genes in Parkinson’s disease
(TY-, ME- red) versus normal skin (NK - green). Gene expression levels are
presented as colour variations from dark blue (high expression) to pale
green (low expression) for each individual sample (columns) and for
each gene (rows)
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protein response, as well as ER and Golgi protein traf-
ficking and transport proteins. Also several of the
downregulated genes play a role in vesicular transport.
In addition, a group of axonemal motor proteins
showed differential expression with light chain dyneins
and myosin being downregulated and heavy chain dyneins
being upregulated in PD. In addition, protein degradation
by the ubiquitin-proteasome system (UPS) is impacted in
PD skin, including neddylation and ubiquitilation of pro-
teins, as well as proteasomal degradation, as demonstrated
by downregulation of 11 members of the proteasome
complex. Only one member of the ubiquitilation process
showed increased expression. Normally the impaired pro-
tein aggregation and degradation initiates the autophagic-
lysosomal response in cells, however in PD skin several
central markers of autophagy were also supressed. In
addition, several phosphatases, proteases and peptidases,
as well as peptidase inhibitors were decreased. Of note
among the dysregulated peptidases are members of the
ADAM metallopeptidase family, members of the matrix
metallopeptidase family and calpain peptidases. Also
several members of the serine/serpine peptidase inhibi-
tors were downregulated in PD skin. In addition to the
above mentioned proteases also cathepsins and cysteine
protease inhibitors were downregulated in PD skin.
Impaired skin homeostasis in PD patients
Our study identified a group of 115 genes regulating epi-
dermal and dermal homeostasis to be affected in PD
patients (see Additional file 1: Table S4.). In accordance
with the overall suppression of gene expression, most
of these genes were downregulated in PD. In regard to
epidermal renewal, a large group of genes participating
in keratinocyte cytodifferentiation was altered in PD
skin, including downregulation of 9 different keratins
and several keratinocyte differentiation factors. Ephrins
also influence the process of keratinocyte proliferation
and differentiation and in our study Ephrin-A1 showed
downregulation, whereas EphA6-receptor showed upregu-
lation in PD skin. Another large set of genes affected in
PD skins involved the process of epidermal cornification
and desquamation, as demonstrated by the suppression of
20 genes from the epidermal differentiation complex
(EDC) including loricrin (the most abundant gene in the
cornified envelope), members of the small proline rich
proteins, the S100 protein family and late cornified enve-
lope proteins. The three members of the stratified epithe-
lium secreted peptides complex (SSC)—dermokine,
suprabasin and keratinocyte differentiation-associated pro-
tein, were also downregulated in PD skin. Another down-
regulated pathway related to cornification in our study,
includes cystatins, cathepsins as well as transglutaminase.
Adding to the complexity of epidermal homeostasis and
permeability are intercellular junctions which regulate the
flow of molecules and pathogens in epithelium. We also
observed altered regulation of several claudins and defen-
sins, which are central players in the structure and main-
tenance of tight junctions, and which also play a role in
the antimicrobial properties of the epidermis and form a
part of the CE. In addition dermokine—a protein known
to be part of a the stratified epithelium secreted peptide
complex, functioning in keratinocyte differentiation and
possibly playing a role in inflammatory response—was
downregulated in PD samples. A few melanocytic genes
were also downregulated, including d-dopachrome tauto-
merase and macrophage migration inhibitory factor, which
both play a role in eumelanin biosynthesis. In regard to
the dermal layer of skin, multiple members of the collagen
family showed increased expression in PD skin, whereas a
few collagens showed decreased expression. In addition, a
large group of genes playing variable roles in cytoskeletal
dynamics and morphology, including the regulation of
actin and tubulin morphology were altered. Lastly, the
antimicrobial defence mechanisms seem also to be affected
in PD skin, as demonstrated by down-regulation of several
defensins, mucins and rnases.
Nuclear processes influenced in PD skin
A large set of differentially regulated genes (128 genes) in
PD skin play a role in nuclear processes and epigenetic
Table 1 Top 10 functional network functions affected in
Parkinson’s disease versus normal skin as analysed by Ingenuity
Pathway Analysis. The first number in the score column reflects
the number of genes in a reference gene set and the second
reflects the number of focus genes altered in our study
Associated Network Function Score/
nr of genes
1 Gene expression, Protein synthesis,
Dermatological diseases and conditions
46/28
2 Dermatological diseases and conditions,
Immunological disease, Inflammatory disease
35/23
3 Cellular assembly and organization,
Behaviour, Cell signalling
34/23
4 Cancer, Immunological disease,
Cellular development
33/22
5 Connective tissue disorder, Dermatological
diseases and conditions,
Developmental disorder
30/21
6 Lipid Metabolism, Molecular Transport,
Small Molecule Biochemistry
28/21
7 Molecular Transport, Neurological Disease,
Psychological Disorders
28/20
8 Cellular Movement, Haematological System
Development and Function, Immune
Cell Trafficking
21/18
9 Cellular Growth and Proliferation,
Haematological System Development
and Function, Tissue Development
21/16
10 Lipid Metabolism, Small Molecule Biochemistry,
Vitamin and Mineral Metabolism
19/16
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regulation (see Additional file 1: Table S5.) 14 genes
participating in different aspects of the cell cycle were
supressed in PD, including cyclins, cyclin dependent
kinases (CDKs) and other cell division cycle associated
genes. Also 14 regulators of basal transcription of RNA
were downregulated, with different RNA polymerase II
polypeptide associated factors, activators of basal tran-
scription and elongation factors being supressed. Another
important category supressed in PD is related to the
reparation and degradation of nuclear and mitochondrial
DNA, with 11 genes including endo- and exo-nucleases,
dnases and growth-arrest associated molecules down-
regulated. A large group of transcription factors were
deregulated in PD skin, several of these controlling various
aspects of skin homeostasis, proliferation and differen-
tiation, but others regulating energy metabolism, cellular
signalling and immune responses. In addition, a large set
of altered genes can be associated to epigenetic regula-
tion. This is highlighted by the down-regulation of
achaete-scute homolog 2, which is known to regulate
various aspects of epigenetics. Also genes related to
chromatin remodelling and DNA binding, transcriptional/
post-transcriptional modification and RNA splicing were
differentially regulated, as well as a large group of
miRNAs, snRNPRs and snoRNAs.
Signalling pathways and tumour genes influenced in
PD skin
We observed a basal deregulation of cellular signalling
pathways and suppression of several oncogenes and
tumorsupressors in PD skin (see Additional file 1:
Table S6.). Several of the central growth and survival
pathways were also altered in PD skin, as highlighted
by suppression of Ras signalling by decreased expres-
sion of central Ras-effectors. Also small-GTPase family
genes and G-protein signalling were affected. In
addition, central effectors of Wnt signalling and several
regulators of NOTCH signalling showed altered levels
in PD skin. PD also impacts fibroblast growth factor,
insulin-like growth factor, transforming growth factor-β,
nuclear factor-κβ, and other central signalling proteins,
such as carcinoembryonic antigen proteins, epidermal
growth factor and vascular endothelial growth factor
family proteins.
Immune pathways affected in PD skin
The most statistically significantly changed gene in our
study was serum amyloid A1 (SAA1), which together with
SAA2 (also downregulated), are known to be major acute
phase proteins, participating in inflammation, but also in
various other processes such as cholesterol metabolism
and amyloid aggregation. Also a large set of chemokines,
cytokines and cluster of differentiation molecules were
altered in PD skin (see Additional file 1: Table S6.).
Also the tumor-necrosis-factor (TNF) family signalling
was induced in PD skin, with several TNF family mem-
bers differentially regulated. Further in regard to
humoral immunity, genes related to the HLA complex
showed differential regulation, such as the HLA-DQA2
which was significantly upregulated in PD skin, of special
interest being that changes in the HLA genes have been
associated with an increased risk for sporadic PD. Also
several complement genes, immunoglobulins, interleukins
and interferon signalling molecules were altered in PD
skin. Lastly the components of cellular immunity
including T-cell signalling, showed alterations in PD skin.
Validation of a gene set by qRT-PCR
A subset of 12 genes showing differential expression in
PD skin samples was selected for validation of RNA
sequencing data by qRT-PCR, in a larger set of patient
and control samples. These genes were chosen due to
the highest differential expression levels in PD samples,
but also because of their potential interest in pathogenic
pathways in PD. The RNAseq and qRT-PCR levels for
the following genes are shown in Additional file 1:
Table S8: SAA-1,-2, hemoglobin α-2 (HBA-2), calmodulin-
like 6 (CALML-6), DiGeorge syndrome critical region
gene 6-like (DGCR-6 L), cystatin E/M (CST E/M), olfac-
tory receptor family 2 subfamily H member 2 (OR2HR),
reactive oxygen species modulator 1 (ROMO-1), ADAM-
like decysin 1 (ADAMDEC), hypocretin (orexin) neuro-
peptide precursor (HCRT), killer cell lectin-like receptor
subfamily C member 3 (KLRC-3), apolipoprotein C-1
(APOC-1).) Although the exact gene expression levels
varied between the two methods, 9 out of 12 genes
were changed in the similar direction.
Discussion
The transcriptomic analyses of PD patients skin revealed
a large set of over 1000 differentially regulated genes.
Interdependent biological and functional networks can
be distinguished among the differentially regulated genes
and the deregulation of these networks demonstrates a
state of severe impairment in basal homeostasis, as well
as decreased defence mechanisms to cellular stress in
PD skin. Our study results correlate with, and further
enhance, the existing knowledge of PD associated
pathogenesis and additionally provide a possible molecular
explanation for the association of PD with melanoma/
non-melanoma skin cancers.
“Skin-Brain” crosstalk in PD – disturbed mitochondrial
and protein homeostasis in skin
A focal point of our study highlights the relevance of
“skin-brain” crosstalk in understanding the pathogenic
mechanisms of neurodegenerative diseases, such as PD.
Our findings support the assumption that the biomolecular
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alterations of PD are systemic and are also reflected in
other non-neuronal cells of the body, demonstrating the
applicability of skin biopsies as an easily accessible ex vivo
solid-tissue based model system, for downstream patho-
genic studies and for possible diagnostic/biomarker dis-
covery. Notably, our study highlights that PD reflection in
skin is dominated by global suppression of central cellular
processes (over 80% of genes were downregulated),
indicating a state of extensive cellular stress and com-
pensatory molecular changes limiting the physiological
functioning to minimum.
The current understanding of PD pathogenesis in the
nervous system, is led by impairment of two major bio-
logical systems: mitochondrial dysfunction and protein
metabolism. One of the most robust findings in our
study, is the evident basal defect in cellular bioenergetics,
metabolism and the impairment of mitochondrial func-
tion. This is initially demonstrated by the suppression of
1/3 of the components of the mitochondrial electron
transfer chain in PD skin, including complexes I, III, IV
and V. In addition, the cellular redox homeostasis, oxida-
tive stress and antioxidant response are supressed in PD
skin. Mitochondrial impairment in PD skin is also demon-
strated by downregulation of genes responsible for
mitochondrial dynamics and transport. Adding to the
impairment, is the suppression of fatty acid biosynthesis
and metabolism. PD has been associated with lipid distur-
bances, including the specific vulnerability of fatty acids to
oxidation, leading to an increase in ROS production and
enhanced susceptibility to oxidative stress, but also in
relation to the direct interactions of α-synuclein with
lipids, as its aggregation is known to occur in the presence
of lipid membranes and free fatty acids [24]. Other
impaired central biosynthetic and metabolic processes
include oxidation of aldehydes, purine and pyrimidine
metabolism, steroidogenesis, amino acid, glucose and
carbohydrate metabolism, as well as calcium, iron and
glycoprotein metabolism. It is noteworthy, that although
most of the effector molecules in the cellular metabolism
pathways were downregulated in our study, we observed
up-regulation of the transcriptional coactivator and
central inducer of mitochondrial biogenesis—PGC-1α,
which controls oxidative metabolism through expres-
sion of genes in the mitochondrial respiratory chain,
and regulates detoxification of reactive oxygen species
[25]. Our finding is in line with a large genome-wide
meta-analysis on PD brain samples, which found PGC-1α
to be the main common pathway to be deregulated
between 17 different microarray sets, with most of the
PGC-1α controlled genes being suppressed in PD samples
[26]. In addition, our study observed regulation of other
transcription factors related to bioenergetics, indicating
that the compensatory changes for disturbed bioenergetics
and cellular metabolism in PD skin are regulated on the
level of central transcriptional control. In addition,
mitochondrial DNA regulation has been associated
with PD and decreased expression of mitochondrial
polymerase –POLRMT, an enzyme which plays a funda-
mental role in expression and replication of the human
mitochondrial genome and in mitochondrial protein
translation, was observed in our study. We also noted
decreased expression of several mitochondrial ribosomal
proteins, which function as components of the mitochon-
drial ribosome and regulate the translation of all the
essential polypeptides of the oxidative phosphorylation
system. Based on the current study results, it can be
concluded that a “basal” transcriptomic defect in cellular
bioenergetics and metabolism exists in PD skin, this
finding correlating with the known understanding of
the pathogenic processes of PD in CNS.
The second most robust finding in our study, is the
involvement of genes related to the processes of protein
metabolism, transport and degradation. Imbalances of
protein homeostasis have been associated with PD
pathogenesis in the nervous system, however our study
demonstrates that protein homeostasis in PD skin is
affected already at the level of ribosomal biogenesis and
basal eukaryotic translation, as seen by downregulation
of a large set of different ribosomal proteins, as well as
several eukaryotic translation initiation and elongation
factors. The downregulation of ribosomal proteins in
response to stress, can be considered compensatory for
limitation of energy expenditure and in order to main-
tain essential cellular functioning, however long-term
inhibition can lead to severe cellular damage and death
[27]. Further, a large group of genes playing a role in
protein post-translational modifications, protein folding,
aggregation and processing in the ER, are affected in
PD skin. Another large group includes proteins partici-
pating in the cellular trafficking of proteins, vesicles and
organelles. Further, the protein degradation machinery of
the UPS is evident in PD skin, highlighted by suppression
of several proteins involved in ubiquitination and neddyla-
tion, as well as downregulation of 11 subunit components
of the proteasome, proteasome assembly chaperones
and maturation proteins. In addition, several central
genes of the autophagic-lysosome cascade are affected,
demonstrating impaired autophagic response in PD skin.
Also, a large group of cellular and lysosomal phospha-
tases, peptidases and proteinases are co-ordinately
deregulated in PD skin, indicating defective protein deg-
radation machinery and impaired proteolysis. Taken
together our findings demonstrate a severe “basal”
impairment of protein homeostasis in PD skin, charac-
terized by suppression of protein translation, cellular
trafficking, as well as dysfunctional protein quality con-
trol by the UPS and impairment of the autophagic
response, which all contribute to the vicious cycle of
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misfolded protein buildup, further contributing to
cytotoxicity.
Impaired skin homeostasis, nuclear processes and
tumorigenic pathways—the mechanistic link for
predisposition to skin cancer in PD patients?
The second focal point of our study enhances the under-
standing of the mechanistic association between skin
cancer and PD, as demonstrated by a basal defect in skin
homeostasis, deregulated nuclear processes, as well as
dysbalanced cellular signalling, tumorigenic pathways
and inflammatory processes—all these alterations pos-
sibly contributing to the specific vulnerability of PD skin
to mutagenic hazards (such as UV radiation, somatic
mutations, genomic instability), which can provide the
basis for the mechanistic link to the increased risk of
skin cancer in this patient population.
Our study data demonstrates direct alteration of skin
physiology in PD patients, characterized by dysregulation
of epidermal renewal/keratinocyte differentiation, cornifi-
cation/desquamation, response to injury and stress, as well
as altered structural and molecular composition of dermis.
We observed differential regulation of a large group of
keratins and several keratin-related proteins, which indi-
cates impaired epithelial differentiation, tissue fragility and
structural integrity of PD skin. Our study revealed a coor-
dinated suppression of parallel pathways of the cornifica-
tion and desquamation processes, highlighted by the
suppression of the EDC, which contains 57 genes crucial
for the differentiation process located within a tight clus-
ter on chromosome 1q21 (20 genes of EDC supressed)
and also ephrin A1, which is a central regulator of epider-
mal growth, located in close proximity to the EDC on
chromosome 1q arm. In addition, we observed the
decreased expression of all genes of the stratified
epithelium-secreted peptide complex, as well as the cysta-
tin/cathepsin/transglutaminase pathway, which regulates
the cross-linking of the CE proteins and influences the
desquamation of the stratum corneum. Further we
observed suppression of several different junction and
desmosome proteins and deregulation of the antimicrobial
defence in PD, indicating that the desmosomal adhesions
and anchoring junctions are defective in PD, thereby
contributing to impairment of structural integrity and
barrier function. In addition, the dermal components of
skin were affected, characterized by altered levels of
several members of the collagen family, as well as
deregulation of cytoskeletal remodelling and dynamics,
these changes contributing to impairment of tissue
elasticity, predisposing to premature aging of skin, and
impacting the structural and compositional remodel-
ling. In conclusion, maintenance of skin homeostasis,
thru a balanced orchestration of regeneration, cell
renewal, differentiation and senescence, is essential to
withstand stress and mutagenic hazard and disruption
of this equilibrium can lead to skin disease, such as
development of cancers.
The second significant category of differentially
expressed genes, with possible impact in both PD and
skin cancer involves nuclear regulation of cellular pro-
cesses in PD skin. This is highlighted by suppression of
cell cycle proteins, such as several cyclins, CDKs, activa-
tors/inhibitors of CDKs and others. In skin, cell cycle
regulation is essential to maintain the homeostatic balance
between proliferation and differentiation, whereby kerati-
nocytes respond to cell cycle insults and DNA damage by
deregulation of the cell cycle and induction of terminal
differentiation [28], however chronic dysregulation can
lead to enhanced predisposition for development of
cancers. Further, our study indicates that several regula-
tors of basal transcription, and a large group of central
transcription factors are deregulated in PD skin, which
act as direct regulators/corepressors of genes regulating
epidermal terminal differentiation (including the EDC),
epithelial-mesenchymal transition, programmed cell
death, oxidative stress and tumorigenesis. Other deregu-
lated transcription factors play more variable roles
regulating cell growth, proliferation, differentiation,
longevity, and acting as downstream targets of multiple
signalling pathways. Another important aspect of PD
and skin cancer crosstalk can be drawn from the
observed downregulation of genes related to DNA/
mtDNA repair and degradation, which can contribute
to buildup of damaged DNA, interfere with normal cellu-
lar functioning and also predispose to tumorigenesis. And
lastly, in regard to nuclear regulation of cellular processes,
a large group of genes in our study was also associated
with the epigenetic regulation of gene expression, as seen
by deregulation of proteins participating in chromatin
remodelling, DNA binding, RNA/DNA processing and
transcriptional/post-transcriptional modification, RNA
splicing, as well as a set of different micro-RNAs, small-
nuclear- and small-nucleolar-RNAs. The deregulation of
cell cycle proteins and transcription factors, as well as the
suppression of DNA repair processes and modification of
epigenetic signalling, might be executed as a compensa-
tory cytoprotective effect against various pro-apoptotic
stimuli from the aspect of PD, however the chronic form
of such stress can also provide the basis for molecular
predisposition to different forms of skin cancers in
these patients.
The third important category in our study, in relation
to PD and skin cancer crosstalk, is associated to cellular
signalling and tumorigenesis. We observed down-
regulation of a large set of tumour suppressors and
oncogenes in PD skin. Further many central intra- and
inter-cellular signalling genes and growth factors were
altered in PD skin, including Ras and other small-
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GTPases, G-protein signalling pathways, WNT, NOTCH
and several others. Perhaps the most prominently
affected signalling pathway in PD skin is related to WNT
signalling, where deregulation of central WNT effectors,
provides one possible mechanistic association between
the processes of epidermal renewal/differentiation,
tumorigenesis and neurodegeneration. WNT signalling
plays a dominant role in controlling the patterning of
skin, influencing the decision of stem cell lineage and in
controlling the functioning of differentiated skin cells,
and disruption of this signalling pathway has been asso-
ciated with the development and progression of both
melanoma and non-melanoma cancers [29]. On the
other hand WNT signalling has been strongly associated
with PD pathogenesis, functioning in midbrain dopa-
minergic neuron development, synaptic plasticity and
transmission. In addition, suppression of several members
of the Ras superfamily indicates dysfunctional growth,
differentiation and survival mechanisms in PD skin,
including cellular proliferation, cytoskeletal dynamics/
morphology, membrane trafficking, cellular adhesion
and vesicular transport.
And lastly, our study indicates dysregulation of immune
pathways in PD skin. The interplay of pro- and anti-
inflammatory signalling, and the discrimination of causal
and effector changes in the context of both PD and cancer
is complex, however chronic inflammation has been
shown to be one of the main factors fostering all stages of
neoplasia, but also one of the pathogenic processes in PD
progression, thus the basal inflammatory dysfunction
associated with PD can thereby contribute to increasing
the risk of cancer development in these patients.
In regard to the existing explanations for the basis of
PD and melanoma crosstalk, most studies have empha-
sized the role of the common skin- and neuro-melanin
pathways during early development, and possible defects
in tyrosine metabolism. Our study did not observe specific
changes in regard to melanin pathways or tyrosine me-
tabolism, however as our study design was set up to
evaluate the gene expression changes occurring in
whole skin of PD, and not specifically the small popula-
tion of melanocytes, it can be that these changes
remained too subtle for detection with our methodology.
Follow-up studies utilizing gene expression profiling of
cell-type specific samples, could provide further assistance
in dissecting the PD related pathways in skin. In addition,
it has been suggested that perturbations on the genetic
level could contribute to the underlying crosstalk between
Fig. 2 A schematic presentation of the manifestation of Parkinson’s Disease in skin, as characterized by an interplay of alterations affecting six
central molecular processes, leading to basal cellular stress and homeostatic imbalance. These processes can be considered as the reflection of
Parkinson’s Disease pathology in skin, but in the setting of internal and external mutagenic hazards, these alterations can also form the underlying
basis for increased risk of skin cancers in these patients
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melanoma and PD, although the majority of our study
subjects (11/12 tested) were not carriers of mutations in
any common PD associated genes (data not shown), the
role of PD-associated genetic variants which can mediate
the expression of quantitative trait locus effects in both
skin and brain, cannot be excluded. One limitation of our
study is the relatively low log2FC levels observed for gene
expression, which might pose difficulties in distinguishing
the true signal from noise, thus it cannot be excluded that
some of the genes with milder expression levels in our
pathway analysis might be attributable to noise. This how-
ever is a common finding in multiple ex vivo gene expres-
sion studies of a chronic disease and as all affected
pathways in our study consisted of multiple genes with
intertwining functions, the general conclusions can be
considered to be valid.
Conclusions
In conclusion, our study (as shown in schematic Fig. 2.)
demonstrates a large basal defect in cellular bioenergetics
and mitochondrial dysfunction, impaired protein me-
tabolism, dysbalanced skin homeostasis, deregulation of
nuclear processes, as well as disturbances in many central
signalling and immune pathways, indicates that the patho-
genic processes associated with neurodegeneration are
occurring also in peripheral tissues, such as skin. Fur-
ther our study concludes that this severe “basal defect”
in cellular homeostasis associated with the pathogenesis
of Parkinson’s disease, could provide a mechanistic
molecular basis for enhanced sensitivity of PD skin to
patients internal (such as genomic instability) and external
mutagenic hazards (such as UV radiation), thus leading to
enhanced predisposition of PD patients for development
of skin cancers and thereby providing a link for the
crosstalk between neurodegenerative disease and cancer.
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